Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities. Methods: A total of 249 patient cases (PAC, 111 cases; UC, 138 cases) collected between June 1995 and July 2009 at Seoul St. Mary’s Hospital were studied. An immunohistochemical evaluation of prostatic markers (prostate-specific antigen [PSA], prostate-specific membrane antigen [PSMA], prostate acid phosphatase [PAP], P501s, NKX3.1, and α-methylacyl coenzyme A racemase [AMACR]) and urothelial markers (CK34βE12, p63, thrombomodulin, S100P, and GATA binding protein 3 [GATA3]) was performed using tissue microarrays from each tumor. Results: The sensitivities of prostatic markers in PAC were 100% for PSA, 83.8% for PSMA, 91.9% for PAP, 93.7% for P501s, 88.3% for NKX 3.1, and 66.7% for AMACR. However, the urothelial markers CK34βE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively. The sensitivities of urothelial markers in UC were 75.4% for CK34βE12, 73.9% for p63, 45.7% for thrombomodulin, 22.5% for S100P, and 84.8% for GATA3. Conversely, the prostatic markers PSA, PSMA, PAP, P501s, NKX3.1, and AMACR were also positive in 9.4%, 0.7%, 18.8%, 0.7%, 0%, and 8.7% of UCs, respectively. Conclusions: Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC. The optimal combination of prostatic and urothelial markers could improve the ability to differentiate PAC from UC pathologically.
Abstract
Background: The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities. Methods: A total of 249 patient cases (PAC, 111 cases; UC, 138 cases) collected between June 1995 and July 2009 at Seoul St. Mary’s Hospital were studied. An immunohistochemical evaluation of prostatic markers (prostate-specific antigen [PSA], prostate-specific membrane antigen [PSMA], prostate acid phosphatase [PAP], P501s, NKX3.1, and α-methylacyl coenzyme A racemase [AMACR]) and urothelial markers (CK34βE12, p63, thrombomodulin, S100P, and GATA binding protein 3 [GATA3]) was performed using tissue microarrays from each tumor. Results: The sensitivities of prostatic markers in PAC were 100% for PSA, 83.8% for PSMA, 91.9% for PAP, 93.7% for P501s, 88.3% for NKX 3.1, and 66.7% for AMACR. However, the urothelial markers CK34βE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively. The sensitivities of urothelial markers in UC were 75.4% for CK34βE12, 73.9% for p63, 45.7% for thrombomodulin, 22.5% for S100P, and 84.8% for GATA3. Conversely, the prostatic markers PSA, PSMA, PAP, P501s, NKX3.1, and AMACR were also positive in 9.4%, 0.7%, 18.8%, 0.7%, 0%, and 8.7% of UCs, respectively. Conclusions: Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC. The optimal combination of prostatic and urothelial markers could improve the ability to differentiate PAC from UC pathologically.
참고문헌 (29)
- Bates AW, "Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases", Histopathology, 36, pp.32~40 (2000)
- Dabbs DJ, "Diagnostic imunohistochemistry", pp.621~625 (2010), Saunders-Elsevier
- Chuang AY, "Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma", Am J Surg Pathol, 31, pp.1246~1255 (2007)
- Varma M, "Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature", Histopathology, 47, pp.1~16 (2005)
- Mhawech P, "Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma", Hum Pathol, 33, pp.1136~1140 (2002)
- Kunju LP, "Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and", or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma, 2006, pp.125, 675~681
- Chibber PJ, "Transitional cell carcinoma involving the prostate", Br J Urol, 53, pp.605~609 (1981)
- Kamoshida S, "Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland", Hum Pathol, 21, pp.1108~1111 (1990)
- Goldstein NS, "Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores", Am J Clin Pathol, 117, pp.471~477 (2002)
- Genega EM, "Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma", Mod Pathol, 13, pp.1186~1191 (2000)
- Marchal C, "Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia", Histol Histopathol, 19, pp.715~718 (2004)
- Bostwick DG, "Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases", Cancer, 82, pp.2256~2261 (1998)
- Silver DA, "Prostate-specific membrane antigen expression in normal and malignant human tissue", Clin Cancer Res, 3, pp.81~85 (1997)
- Chang SS, "Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma", Urology, 57, pp.1179~1183 (2001)
- Sweat SD, "Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases", Urology, 52, pp.637~640 (1998)
- Lane Z, "Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder", Am J Surg Pathol, 32, pp.1322~1326 (2008)
- Bassily NH, "Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma", Am J Clin Pathol, 113, pp.383~388 (2000)
- Xu J, "Identification and characterization of prostein, a novel prostate-specific protein", Cancer Res, 61, pp.1563~1568 (2001)
- Kalos M, "Prostein expression is highly restricted to normal and malignant prostate tissues", Prostate, 60, pp.246~256 (2004)
- He WW, "A novel human prostate-spe cific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer", Genomics, 43, pp.69~77 (1997)
- Bowen C, "Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression", Cancer Res, 60, pp.6111~6115 (2000)
- Gelmann EP, "Expression of NKX3.1 in normal and malignant tissues", Prostate, 55, pp.111~117 (2003)
- Aslan G, "Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features", Pathol Res Pract, 202, pp.93~98 (2006)
- Jiang Z, "Using an AMACR (P504S)", 34betaE12, Am J Clin Pathol, pp.2005, 123[DOI]
- Parker DC, "Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas", Am J Surg Pathol, 27, pp.1~10 (2003)
- Parwani AV, "Prostate carcinoma with squamous differentiation: an analysis of 33 cases", Am J Surg Pathol, 28, pp.651~657 (2004)
- Comperat E, "Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma: a tissue microarray study of 158 cases", Virchows Arch, 448, pp.319~324 (2006)
- Higgins JP, "Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray", Am J Surg Pathol, 31, pp.673~680 (2007)
- Chang A, "Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung", Am J Surg Pathol, 36, pp.1472~1476 (2012)